drugset / Trial / NCT01166984
AB103 Peptide Antagonist in Healthy Volunteers
RandomizedParallel-groupTriple-blindOther
Summary
The primary objective of this study is to establish the safety profile and maximum tolerated dose (MTD) of AB103 given as a single intravenous (IV) infusion in healthy volunteers.
Timeline
- Start
- 2010-09
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Reltecimod | Peptide | 7.5 ug/kg | Intravenous |
| Subject | Reltecimod | Peptide | 37.5 ug/kg | Intravenous |
| Subject | Reltecimod | Peptide | 150 ug/kg | Intravenous |
| Subject | Reltecimod | Peptide | 450 ug/kg | Intravenous |
Indications
No indication recorded.